Outcomes from Adrenocortical Carcinoma
Adrenocortical carcinoma has a poor prognosis with 5-year overall survival less than 15% in advanced disease, though outcomes vary substantially based on stage at diagnosis, with stage I-II disease achieving significantly better survival than metastatic disease. 1
Survival Outcomes by Stage
The prognosis of ACC is heavily stage-dependent, with dramatic differences in survival:
- Stage I: Median survival of 24.1 years 2
- Stage II: Median survival of 6.08 years 2
- Stage III: Median survival of 3.47 years 2
- Stage IV (advanced/metastatic): Median survival of 0.89 years, with 5-year overall survival <15% 1, 2
The overall median survival across all stages is approximately 2-3 years 3, 2. However, considerable heterogeneity exists, with prolonged survival reported in patients with resectable oligometastatic disease and long intervals between recurrences 1.
Recurrence Risk
The risk of recurrence after complete surgical resection is substantial, with the highest frequency occurring within the first 2 years post-operatively. 1
- Median local recurrence-free time is approximately 1 year after surgical resection 2
- Recurrence rates vary but are significant even after complete resection 4
- Positive surgical margins and advanced disease stage are strongly associated with local recurrence 2
Prognostic Factors Affecting Outcomes
Factors Associated with Poor Survival:
The ENSAT stage has the most dominant effect on prognosis, followed by age, tumor functionality, and resection status. 5, 2
- Advanced ENSAT stage: Hazard ratio 3.60 for overall survival 6
- Large vessel invasion: Hazard ratio 5.19 for overall survival 6
- Older age at diagnosis: Independently associated with worse survival 5, 2
- Functioning tumors: Associated with poor survival outcomes 2
- Incomplete surgical resection (R1/RX): Significantly worsens prognosis 2
- Ki-67 index >10%: Defines high-risk category for recurrence 1
Factors Associated with Better Outcomes:
- Complete (R0) surgical resection: Essential for improved survival 1
- Mitotane therapy: Hazard ratio 0.27 for overall survival, particularly beneficial in stage IV disease 6
- Disease-free interval >9 months after primary surgery: Predictive of better response to local therapies 7
- Resectable oligometastatic disease: Associated with prolonged survival 1
Quality of Life Considerations
Hormone-related symptoms from functioning tumors significantly impact quality of life and require management alongside oncologic treatment. 1
- 41.8% of ACC cases are hormonally functioning tumors 2
- Functioning tumors are associated with worse prognosis 2
- Control of tumor growth and hypersecretion-related symptoms are primary therapeutic goals in advanced disease 1
Treatment Impact on Outcomes
Mitotane use improves clinical outcomes, particularly in stage IV disease, though overall prognosis remains poor despite aggressive treatment. 6, 3
- Response rates to mitotane monotherapy in metastatic ACC vary between 13-35% 1
- Treatment at high-volume centers is associated with more aggressive surgical resection and chemotherapy use, though this does not translate to significantly improved survival 3
- Local therapies (radiofrequency ablation, transarterial chemoembolization) achieve local disease control in a significant percentage of patients with limited disease 8, 7
Common Pitfalls
Avoid underestimating the importance of complete surgical resection and experienced surgical expertise, as incomplete resections dramatically worsen outcomes. 2